Shire seeks OK of ADHD drug in adults

PHILADELPHIA, June 29 (UPI) -- U.S. firm Shire said Friday it has filed for U.S. approval of Vyvanse for the treatment of attention deficit hyperactivity disorder in adults.

The company said the product -- approved earlier this year for children aged six to 12 years with ADHD -- is a prodrug stimulant that remains inactive until it is metabolized in the body, at which time the drug's active ingredient d-amphetamine is released.

Shire said its application is subject to a 10-month review by the Food and Drug Administration.

"ADHD is a treatable disorder that affects adults as well as children," said Shire CEO Matthew Emmens. "We are pleased with the results of Vyvanse studies conducted in adults and we believe this product will meet an important need in the adult ADHD marketplace."